Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4

Qiong Ding, Kitora Tanigawa, Jun Kaneko, Mamoru Totsuka, Yoshinori Katakura, Etsuko Imabayashi, Hiroshi Matsuda, Tatsuhiro Hisatsune

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In a previously reported double-blind, randomized controlled trial (RCT), we demonstrated that daily supplementation with anserine (750 mg) and carnosine (250 mg) improves brain blood flow and memory function in elderly people. Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease. We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months. Subjects were assessed at the start and end of the trial using several neuropsychological tests, including the Wechsler Memory Scale-Logical Memory (WMS-LM). We also collected two types of MRI data, arterial spin labeling (ASL) and diffusion tensor imaging (DTI) at the start and end of the trial. We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001). Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups. The effect of ACS in preserving brain structure and function in elderly people carrying APOE4 should be verified by further studies.

Original languageEnglish
Pages (from-to)334-345
Number of pages12
JournalAging and Disease
Volume9
Issue number3
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Anserine
Carnosine
Brain
Wechsler Scales
Diffusion Tensor Imaging
Randomized Controlled Trials
Blood Preservation
Placebos
Neuropsychological Tests
Alzheimer Disease
Alleles
Genotype

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cell Biology

Cite this

Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4. / Ding, Qiong; Tanigawa, Kitora; Kaneko, Jun; Totsuka, Mamoru; Katakura, Yoshinori; Imabayashi, Etsuko; Matsuda, Hiroshi; Hisatsune, Tatsuhiro.

In: Aging and Disease, Vol. 9, No. 3, 01.06.2018, p. 334-345.

Research output: Contribution to journalArticle

Ding, Q, Tanigawa, K, Kaneko, J, Totsuka, M, Katakura, Y, Imabayashi, E, Matsuda, H & Hisatsune, T 2018, 'Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4', Aging and Disease, vol. 9, no. 3, pp. 334-345. https://doi.org/10.14336/AD.2017.0809
Ding, Qiong ; Tanigawa, Kitora ; Kaneko, Jun ; Totsuka, Mamoru ; Katakura, Yoshinori ; Imabayashi, Etsuko ; Matsuda, Hiroshi ; Hisatsune, Tatsuhiro. / Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4. In: Aging and Disease. 2018 ; Vol. 9, No. 3. pp. 334-345.
@article{797eb5b884604619b4c7d83764d216f1,
title = "Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4",
abstract = "In a previously reported double-blind, randomized controlled trial (RCT), we demonstrated that daily supplementation with anserine (750 mg) and carnosine (250 mg) improves brain blood flow and memory function in elderly people. Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease. We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months. Subjects were assessed at the start and end of the trial using several neuropsychological tests, including the Wechsler Memory Scale-Logical Memory (WMS-LM). We also collected two types of MRI data, arterial spin labeling (ASL) and diffusion tensor imaging (DTI) at the start and end of the trial. We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001). Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups. The effect of ACS in preserving brain structure and function in elderly people carrying APOE4 should be verified by further studies.",
author = "Qiong Ding and Kitora Tanigawa and Jun Kaneko and Mamoru Totsuka and Yoshinori Katakura and Etsuko Imabayashi and Hiroshi Matsuda and Tatsuhiro Hisatsune",
year = "2018",
month = "6",
day = "1",
doi = "10.14336/AD.2017.0809",
language = "English",
volume = "9",
pages = "334--345",
journal = "Aging and Disease",
issn = "2152-5250",
publisher = "International Society on Aging and Disease",
number = "3",

}

TY - JOUR

T1 - Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4

AU - Ding, Qiong

AU - Tanigawa, Kitora

AU - Kaneko, Jun

AU - Totsuka, Mamoru

AU - Katakura, Yoshinori

AU - Imabayashi, Etsuko

AU - Matsuda, Hiroshi

AU - Hisatsune, Tatsuhiro

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In a previously reported double-blind, randomized controlled trial (RCT), we demonstrated that daily supplementation with anserine (750 mg) and carnosine (250 mg) improves brain blood flow and memory function in elderly people. Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease. We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months. Subjects were assessed at the start and end of the trial using several neuropsychological tests, including the Wechsler Memory Scale-Logical Memory (WMS-LM). We also collected two types of MRI data, arterial spin labeling (ASL) and diffusion tensor imaging (DTI) at the start and end of the trial. We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001). Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups. The effect of ACS in preserving brain structure and function in elderly people carrying APOE4 should be verified by further studies.

AB - In a previously reported double-blind, randomized controlled trial (RCT), we demonstrated that daily supplementation with anserine (750 mg) and carnosine (250 mg) improves brain blood flow and memory function in elderly people. Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease. We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months. Subjects were assessed at the start and end of the trial using several neuropsychological tests, including the Wechsler Memory Scale-Logical Memory (WMS-LM). We also collected two types of MRI data, arterial spin labeling (ASL) and diffusion tensor imaging (DTI) at the start and end of the trial. We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001). Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups. The effect of ACS in preserving brain structure and function in elderly people carrying APOE4 should be verified by further studies.

UR - http://www.scopus.com/inward/record.url?scp=85048177069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048177069&partnerID=8YFLogxK

U2 - 10.14336/AD.2017.0809

DO - 10.14336/AD.2017.0809

M3 - Article

AN - SCOPUS:85048177069

VL - 9

SP - 334

EP - 345

JO - Aging and Disease

JF - Aging and Disease

SN - 2152-5250

IS - 3

ER -